ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

CD28

CD28 molecule · CD molecules

7 programs in company-led studies act on CD28, from 6 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnson–phase 322 runningFOLH1a judged reading
REGN17372ruleRegeneron Pharmaceuticals–phase 211 runningCD3E, GPRC5Dthe studies' text
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312ruleCytoCares–phase 144 runningCD19, CD3ENCIt
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencor–phase 121 runningCD276NCIt
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564ruleRondo Therapeutics–phase 111 runningNECTIN4NCIt
HLX3901Fosun Pharma–phase 111 runningCD3E, DLL3the company's pipeline
HLX3902Fosun Pharma–phase 111 runningCD3E, STEAP1the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.